| Dr Cyrus Golshani, MD | |
|
3975 Fair Ridge Dr Ste 200, Fairfax, VA 22033-2911 | |
| (703) 289-0443 | |
| Not Available |
| Full Name | Dr Cyrus Golshani |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 10 Years |
| Location | 3975 Fair Ridge Dr Ste 200, Fairfax, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972921864 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 0101267228 (Virginia) | Primary |
| 207W00000X | Ophthalmology | D0091753 (Maryland) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virginia Retina Specialists | 0446558183 | 4 |
News Archive
President Joe Biden's "Build Back Better" social spending bill passed the House last week, but the legislation faces a new and different set of hurdles in the Senate, where it will need the support of every single Democrat, plus approval by the Senate parliamentarian.
Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A collaborative research study among investigators at Wayne State University, the Mayo Clinic and Johns Hopkins Medicine shows that steroids attached to the dendrimers targeted the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision.
From 2006 through 2014, there was a decrease in newly registered NIH-funded trials, whereas industry-funded trials increased substantially, based on trials registered in ClinicalTrials.gov. The study appears in the December 15 issue of JAMA.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
› Verified 3 days ago
| Entity Name | Virginia Retina Specialists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770943565 PECOS PAC ID: 0446558183 Enrollment ID: O20170926003098 |
News Archive
President Joe Biden's "Build Back Better" social spending bill passed the House last week, but the legislation faces a new and different set of hurdles in the Senate, where it will need the support of every single Democrat, plus approval by the Senate parliamentarian.
Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A collaborative research study among investigators at Wayne State University, the Mayo Clinic and Johns Hopkins Medicine shows that steroids attached to the dendrimers targeted the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision.
From 2006 through 2014, there was a decrease in newly registered NIH-funded trials, whereas industry-funded trials increased substantially, based on trials registered in ClinicalTrials.gov. The study appears in the December 15 issue of JAMA.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cyrus Golshani, MD 3975 Fair Ridge Dr Ste 200, Fairfax, VA 22033-2911 Ph: (703) 289-0443 | Dr Cyrus Golshani, MD 3975 Fair Ridge Dr Ste 200, Fairfax, VA 22033-2911 Ph: (703) 289-0443 |
News Archive
President Joe Biden's "Build Back Better" social spending bill passed the House last week, but the legislation faces a new and different set of hurdles in the Senate, where it will need the support of every single Democrat, plus approval by the Senate parliamentarian.
Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A collaborative research study among investigators at Wayne State University, the Mayo Clinic and Johns Hopkins Medicine shows that steroids attached to the dendrimers targeted the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision.
From 2006 through 2014, there was a decrease in newly registered NIH-funded trials, whereas industry-funded trials increased substantially, based on trials registered in ClinicalTrials.gov. The study appears in the December 15 issue of JAMA.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
› Verified 3 days ago
Dr. David Benjamin Summer, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3031 Javier Rd, Suite 300, Fairfax, VA 22031 Phone: 703-698-8880 Fax: 703-698-8884 | |
Dr. James W Slack, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 12255 Fair Lakes Parkway, Fairfax, VA 22033 Phone: 703-934-5820 Fax: 703-934-5290 | |
Dr. John C Baldinger, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3025 Hamaker Ct Ste 101, Fairfax, VA 22031 Phone: 703-876-9630 Fax: 703-876-0163 | |
Dr. Minh-phuong Lu Doan, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 12255 Fair Lakes Pkwy, Kaiser Permanente, Fairfax, VA 22033 Phone: 702-934-5700 | |
Dr. Kristen Elizabeth Dunbar, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3998 Fair Ridge Dr Ste 105, Fairfax, VA 22033 Phone: 571-349-2191 Fax: 571-349-2211 | |
John William Josephson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3998 Fair Ridge Dr Ste 105, Fairfax, VA 22033 Phone: 571-349-2191 Fax: 571-349-2211 | |
Dr. Jonathan Taylormoore, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 3023 Hamaker Ct Ste 500, Fairfax, VA 22031 Phone: 703-876-2788 Fax: 571-776-3190 |